More importantly, co-treatment with a nonselective β-blocker, propranolol, abrogated the increased AF susceptibility in the BO group, suggesting that CaMKII-mediated RyR2 phosphorylation in the atrium of the BO group might be regulated by β-adrenergic signaling. The gene discussed is RYR2; the disease is atrial fibrillation.